Trial · NCT00506675

Combined Patching-Atropine for Residual Amblyopia

NCT00506675, Phase 3, Terminated, Jaeb Center for Health Research; results first posted 2011-03-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Combined Patching-Atropine for Residual Amblyopia. Trials, record NCT00506675. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00506675

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Combined Patching-Atropine for Residual Amblyopia
NCT number: NCT00506675
Status: Terminated
Phases: Phase 3
Enrollment: 55 participants, actual
Lead sponsor: Jaeb Center for Health Research
Conditions: Amblyopia
Interventions: Patching, Atropine, Patching, Atropine
First posted: 2007-07-25
Last updated: 2016-07-13
Results first posted: 2011-03-23
Limitations and caveats: This trial was stopped after 18 months due to inadequate recruitment.

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	10 Weeks	Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to \<7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).
Primary	Mean (SD) Distribution of Visual Acuity at 10 Weeks	10 Weeks	Visual acuity was measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol resulting in a Snellen acuity score that can range from 20/16 to 20/800 for ages 3 to \<7; or with the electronic early treatment diabetic retinopathy study (E-ETDRS) method for 7 to \<10 year olds which resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best. Scores were converted to log of minimum angle of resolution (logMAR) equivalents for analyses (lower logMAR value is better than higher logMAR).
Primary	Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks	baseline to 10 Weeks	Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.
Primary	Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam	baseline to 10 Weeks	Change in logMAR from baseline to 10 weeks was calculated, with positive difference indicating improvement. Note one logMAR line = 5 letters or one Snellen line equivalent.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	10 Weeks	participants	NUMBER
PRIMARY	Mean (SD) Distribution of Visual Acuity at 10 Weeks	10 Weeks	logMAR	MEAN
PRIMARY	Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks	baseline to 10 Weeks	Participants	NUMBER
PRIMARY	Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam	baseline to 10 Weeks	logMAR	MEAN

Source ClinicalTrials.gov

Results by group38

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Intensive	20/125 (0.84 to 0.76 logMAR)	0	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Weaning	20/125 (0.84 to 0.76 logMAR)	1	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Intensive	20/100 (0.74 to 0.66 logMAR)	0	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Weaning	20/100 (0.74 to 0.66 logMAR)	0	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Intensive	20/80 (0.64 to 0.56 logMAR)	1	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Weaning	20/80 (0.64 to 0.56 logMAR)	1	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Intensive	20/63 (0.54 to 0.46 logMAR)	1	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Weaning	20/63 (0.54 to 0.46 logMAR)	4	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Intensive	20/50 (0.44 to 0.36 logMAR)	4	participants
Distribution of Amblyopic Eye Visual Acuity at 10 Weeks	Weaning	20/50 (0.44 to 0.36 logMAR)	0	participants

1 to 10 of 38Source ClinicalTrials.gov

See all 38 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Intensive	27
Overall Study	STARTED	Weaning	28
Overall Study	COMPLETED	Intensive	27
Overall Study	COMPLETED	Weaning	28
Overall Study	NOT COMPLETED	Intensive	0
Overall Study	NOT COMPLETED	Weaning	0

Source ClinicalTrials.gov

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Light sensitivity	General disorders	Intensive	6	27	6
other	Light sensitivity	General disorders	Weaning	0	28	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Intensive
Total, all-cause mortality	Weaning
Total, other adverse events	Intensive	6	27
Total, other adverse events	Weaning	0	28
Total, serious adverse events	Intensive	0	27
Total, serious adverse events	Weaning	0	28

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21746992	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10EY011751	Pediatric Eye Disease Investigator Group Coordinating Center	KRAKER, RAYMOND	JAEB CENTER FOR HEALTH RESEARCH, INC.	NATIONAL EYE INSTITUTE	1997 to 2018

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Intensive vs Weaning: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00506675

GET https://conductscience.org/api/trials/v1/NCT00506675/results?page=2

API reference For AI assistants